Global Central Nervous System Disorders Therapeutics Market 2016-2020

Publisher Name :
Date: 22-Sep-2016
No. of pages: 147
Inquire Before Buying

CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.

The analysts forecast global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • GlaxoSmithKline

  • Pfizer

  • Eli Lilly

  • Janssen Pharmaceuticals

  • Novartis


Other prominent vendors


  • AB Science

  • AbbVie

  • Abital Pharma

  • Acorda Therapeutics

  • Active Biotech

  • Adamas Pharmaceuticals

  • Addex Therapeutics

  • Akorn

  • Alcobra

  • Alexza Pharmaceuticals

  • Alkermes

  • Amarantus

  • Aprecia Pharmaceuticals

  • Archer Pharmaceuticals

  • Astellas

  • AstraZeneca

  • Aurobindo Pharma

  • Auspex Pharmaceuticals

  • Avanir Pharmaceuticals

  • Biscayne Pharmaceuticals

  • Boehringer Ingelheim

  • Cerecor

  • Concordia

  • Convergence Pharmaceuticals

  • Curemark

  • CURx Pharmaceuticals

  • Dainippon Sumitomo Pharma

  • Dart NeuroScience

  • Delpor

  • Desitin Arzneimittel

  • D-Pharm

  • Edgemont Pharmaceuticals

  • Endo International

  • E-Therapeutics

  • Euthymics

  • Evotec

  • F. Hoffmann-La Roche

  • Fabre-Kramer Pharmaceuticals

  • Forum Pharmaceuticals

  • Gedeon Richter

  • Glenmark

  • Grupo Ferrer Internacional

  • GW Pharmaceuticals

  • H. Lundbeck

  • Hisamitsu

  • Impax

  • Insero Health

  • INSYS Therapeutics

  • Intellipharmaceutics

  • Intra-Cellular Therapies

  • Ipsen

  • Kyowa Hakko Kirin

  • Ligand Pharmaceuticals

  • Lupin

  • MarcoPolo Pharmaceuticals

  • Marinus Pharmaceuticals

  • Meda AB

  • Merck

  • Mitsubishi Tanabe

  • MSI Methylation Sciences

  • Mylan

  • Naurex

  • Neuralstem

  • Neurelis

  • Neurovance

  • Nobelpharma

  • Noven Pharmaceuticals

  • Omeros

  • Opexa

  • Opko Health

  • Orion

  • Ophelia Pharmaceutical

  • Otsuka Pharmaceuticals

  • Palobiofarma

  • Par Pharmaceuticals

  • Pierre Fabre

  • Prana Biotechnology

  • Raptor Pharmaceutical

  • Reviva Pharmaceuticals

  • SAGE Therapeutics

  • Sanofi

  • SciFlour

  • Sedor Pharmaceuticals

  • Shire

  • Siena Biotech

  • SK Biopharmaceuticals

  • SOM Biotech

  • Somerset Pharmaceuticals

  • STADA Arzneimittel

  • Sun Pharmaceuticalc

  • Sunovion Pharmaceuticals

  • Supernus Pharmaceuticals

  • Suven

  • Takeda Pharmaceuticals

  • Teva Pharmaceuticals

  • Torrent Pharmaceuticals

  • Tris Pharma

  • Turing Pharmaceuticals

  • UCB

  • US WorldMeds

  • Valeant Pharmaceuticals

  • Zinfandel Pharmaceuticals

  • Zogenix


Market driver


  • New DMD approvals for AD, PD, and MS

  • For a full, detailed list, view our report


Market challenge


  • High failure rates of late-stage products in clinical trials

  • For a full, detailed list, view our report


Market trend


  • Increased uptake of new-generation drugs

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global Central Nervous System Disorders Therapeutics Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Pipeline portfolio
Phase III pipeline portfolio: Global CNS disorders therapeutics market
Phase II pipeline portfolio: Global CNS disorders therapeutics market
Phase I pipeline portfolio: Global CNS disorders therapeutics market
Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market

PART 06: Market landscape
Market overview
Five forces analysis

PART 07: Market segmentation by type of disease
Global depression drugs market
Global MS drugs market
Global schizophrenia drugs market
Global bipolar disorder therapeutics market
Global AD drugs market
Global epilepsy drugs market
Global PD drugs market

PART 08: Geographical segmentation
CNS disorders therapeutics market in Americas
CNS disorders therapeutics market in EMEA
CNS disorders therapeutics market in APAC

PART 09: Market drivers
Special regulatory designations for CNS disorders
New DMD approvals for AD, PD, and MS
Development of novel therapeutics using innovative technologies
High growth potential of mAbs

PART 10: Impact of drivers

PART 11: Market challenges
High failure rates of late-stage products in clinical trials
Growing use of non-invasive neuromodulation and seizure management devices
Unavailability of standard diagnostic methods
Increase in rehabilitation programs
Social stigma associated with CNS diseases

PART 12: Impact of drivers and challenges

PART 13: Market trends
Popularity of me-too drugs
Increased uptake of new-generation drugs
Reformulation of marketed drugs
Focus on regenerative therapies for CNS disorders
Increase in use of LAI antipsychotics

PART 14: Vendor landscape 0
Competitive scenario 0
Key news 3
Glaxo Smith Kline 7
Pfizer 2
Eli Lilly 8
Janssen Pharmaceuticals 3
Novartis 8
Other prominent vendors 4

PART 15: Appendix 4
List of abbreviations 46

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global CNS disorders therapeutics market snapshot
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Key buying criteria for CNS drugs 2015
Exhibit 05: Share of pipeline molecules in global CNS disorders therapeutics market
Exhibit 06: Prevalence of dementia in various regions (millions)
Exhibit 07: Revenues of top-selling CNS drugs (2013-2015)
Exhibit 08: Global CNS disorders therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 09: Global CNS disorders therapeutics market 2015-2020 ($ billions)
Exhibit 10: Impact of drivers and challenges on global CNS disorders therapeutics market
Exhibit 11: Five forces analysis
Exhibit 12: Global CNS disorders therapeutics market: Segmentation by application (2015-2020)
Exhibit 13: Global CNS disorders therapeutics market: Segmentation by type of disease 2015
Exhibit 14: Global CNS disorders therapeutics market segmentation: Growth cycle analysis
Exhibit 15: Global depression drugs market 2015-2020 ($ billions)
Exhibit 16: Opportunity analysis of global depression drugs market
Exhibit 17: Global MS drugs market 2015-2020 ($ billions)
Exhibit 18: Opportunity analysis of global MS drugs market
Exhibit 19: Global schizophrenia drugs market 2015-2020 ($ billions)
Exhibit 20: Opportunity analysis of global schizophrenia drugs market
Exhibit 21: Global bipolar disorder therapeutics market 2015-2020 ($ billions)
Exhibit 22: Opportunity analysis of global bipolar disorder therapeutics market
Exhibit 23: Population aged 60 years and above in millions (1950-2050)
Exhibit 24: Global AD drugs market 2015-2020 ($ billions)
Exhibit 25: Opportunity analysis of global AD drugs market
Exhibit 26: Global epilepsy drugs market 2015-2020 ($ billions)
Exhibit 27: Percentage share of marketed antiepileptic drugs based on mechanism of action
Exhibit 28: Opportunity analysis of global epilepsy drugs market
Exhibit 29: Global PD drugs market 2015-2020 ($ billions)
Exhibit 30: Opportunity analysis of global PD drugs market
Exhibit 31: Global CNS disorders therapeutics market: Geography outlook (2015-2020)
Exhibit 32: Global CNS disorders therapeutics market: Geography outlook 2015
Exhibit 33: Global CNS disorders therapeutics market segmentation by geography: Market growth lifecycle analysis 2015
Exhibit 34: Global CNS disorders market revenue/growth outlook in different countries/regions 2015
Exhibit 35: Global CNS disorders therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 36: Opportunity analysis of CNS disorders therapeutics market in Americas
Exhibit 37: Projected prevalence rates of AD in Americas (2010-2050) (millions)
Exhibit 38: CNS disorders therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 39: Percentage share of CNS disorders therapeutics market in Americas by geography 2015
Exhibit 40: Opportunity analysis of CNS disorders therapeutics market in EMEA
Exhibit 41: CNS disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 42: Opportunity analysis of CNS disorders therapeutics market in APAC
Exhibit 43: CNS disorders therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 44: Few of the late-stage mAbs under development for various CNS disorders
Exhibit 45: Impact of drivers
Exhibit 46: Common disorders that co-exist with bipolar disorder
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Impact of trends on global CNS disorders therapeutics market
Exhibit 49: Planned clinical trials of iPS cell-based therapies
Exhibit 50: Position of key vendors in the global CNS disorders therapeutics market 2015
Exhibit 51: Geographical presence of key vendors
Exhibit 52: Company portfolio analysis in global CNS disorders therapeutics market 2016-2020
Exhibit 53: GlaxoSmithKline: Profile
Exhibit 54: GlaxoSmithKline: Sales of top-selling CNS drugs ($ millions)
Exhibit 55: GlaxoSmithKline: Metrics analysis
Exhibit 56: GlaxoSmithKline: Growth strategy matrix
Exhibit 57: GlaxoSmithKline: Opportunity assessment
Exhibit 58: Pfizer: Profile
Exhibit 59: Sales of CNS drugs ($ millions)
Exhibit 60: Pfizer: Metrics analysis
Exhibit 61: Pfizer: Growth strategy matrix
Exhibit 62: Pfizer: Opportunity assessment
Exhibit 63: Eli Lilly: Profile
Exhibit 64: Eli Lilly: Sales of top-selling CNS drugs ($ millions)
Exhibit 65: Eli Lilly: Metrics analysis
Exhibit 66: Eli Lilly: Growth strategy matrix
Exhibit 67: Eli Lilly: Opportunity assessment
Exhibit 68: Janssen Pharmaceuticals: Profile
Exhibit 69: Janssen Pharmaceuticals: Sales of CNS drugs ($ millions)
Exhibit 70: Janssen Pharmaceuticals: Metrics analysis
Exhibit 71: Janssen Pharmaceuticals: Growth strategy matrix
Exhibit 72: Janssen Pharmaceuticals: Opportunity assessment
Exhibit 73: Novartis: Profile
Exhibit 74: Novartis: Sales of few major CNS drugs ($ millions)
Exhibit 75: Novartis: Metrics analysis
Exhibit 76: Novartis growth strategy matrix
Exhibit 77: Novartis: Opportunity assessment

  • Global Luxury Apparels Market To Do Well Owing To Numerous International Brands
    The global luxury apparels market is fired by the intensifying number of fashion marques and many designers getting wide-ranging clienteles in the form of cost-effective products. The global luxury apparels market was at US$1, 8842.69 million in 2015 and is forecast to reach US$60,793.7 million by the end of 2024. This segment of luxury goods [...]
  • Global Health and Wellness Market Boosted By Organic Products and Wearables
    Healthcare has constantly been a profitable area where buyers spend belligerently. But now, with increasing disposable earnings amid the city population and ground-breaking approaches and innovative products being developed, the overall health and wellness market is estimated for a healthy prospect. The health and wellness market is presently very dynamic owing to growing alertness amongst [...]
  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 509
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their co......
  • Spinal Cord Injury - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 192
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2016, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and s......
  • Herpes Simplex Encephalitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Herpes Simplex Encephalitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Herpes Simplex Encephalitis Report is to understand the market and pipeline status of the drugs around the Herpes Simplex Encephalitis to explore the generic development opportunities, licensing opportunities a......
  • Acute Spinal Cord Injury-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Acute Spinal Cord Injury-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Acute Spinal Cord Injury. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collabora......
  • Meningitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Meningitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Meningitis Report is to understand the market and pipeline status of the drugs around the Meningitis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipel......
  • Meningitis-API Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Bacterial (Pyogenic) Meningitis-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Bacterial (Pyogenic) Meningitis-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Bacterial (Pyogenic) Meningitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licens......
  • Spinal Cord Injury-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Spinal Cord Injury-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Spinal Cord Injury Report is to understand the market and pipeline status of the drugs around the Spinal Cord Injury to explore the generic development opportunities, licensing opportunities and to gain competitive adva......
  • Global Spinal Cord Partnering 2010 to 2016
    Published: 01-Nov-2016        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understandi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs